Statera BioPharma (FRA:7CB) Ending Cash Position: €0.51 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Ending Cash Position?

Statera BioPharma FRA:7CB 20 Ending Cash Position is €0.51 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Ending Cash Position for the quarter that ended in Sep. 2022 was €0.51 Mil.

Statera BioPharma's quarterly Ending Cash Position increased from Mar. 2022 (€0.14 Mil) to Jun. 2022 (€0.52 Mil) but then declined from Jun. 2022 (€0.52 Mil) to Sep. 2022 (€0.51 Mil).

Statera BioPharma's annual Ending Cash Position increased from Dec. 2019 (€0.00 Mil) to Dec. 2020 (€0.49 Mil) and increased from Dec. 2020 (€0.49 Mil) to Dec. 2021 (€6.06 Mil).

Statera BioPharma Ending Cash Position Related Terms

Statera BioPharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Ending Cash Position Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Ending Cash Position
0.00 0.49 6.06

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 12.08 6.06 0.14 0.52 0.51
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Statera BioPharma's Ending Cash Position for the fiscal year that ended in Dec. 2021 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.526+5.532
=6.06

Statera BioPharma's Ending Cash Position for the quarter that ended in Sep. 2022 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.56+-0.049
=0.51

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €0.51 Mil mean?
Statera BioPharma (FRA:7CB) has a Ending Cash Position of €0.51 Mil as of Sep. 2022. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Ending Cash Position too high?
Statera BioPharma's current Ending Cash Position is €0.51 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Ending Cash Position compare to NRBO and PALI?
Statera BioPharma's Ending Cash Position of €0.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Ending Cash Position is €0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Ending Cash Position of €0.51 Mil. The current Ending Cash Position is €0.51 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Ending Cash Position is €0.51 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price